Primary Immunization of Human Papillomavirus Vaccine in the Pediatric Population: What Is the Verdict Now?

about

Primary Immunization of Human Papillomavirus Vaccine in the Pediatric Population: What Is the Verdict Now?

Item

http://www.wikidata.org/entity/Q39306396

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Primary Immunization of Human ...... tion: What Is the Verdict Now?

@en

Primary Immunization of Human ...... tion: What Is the Verdict Now?

@nl

type

Item

label

Primary Immunization of Human ...... tion: What Is the Verdict Now?

@en

Primary Immunization of Human ...... tion: What Is the Verdict Now?

@nl

prefLabel

Primary Immunization of Human ...... tion: What Is the Verdict Now?

@en

Primary Immunization of Human ...... tion: What Is the Verdict Now?

@nl

P1476

Primary Immunization of Human ...... tion: What Is the Verdict Now?

@en

P2093

Aubrey N Jones

http://www.w3.org/2001/XMLSchema#string

Jenna W Bartlett

http://www.w3.org/2001/XMLSchema#string

Rebecca A Bates

http://www.w3.org/2001/XMLSchema#string

Tsz-Yin So

http://www.w3.org/2001/XMLSchema#string

P2860

Epidemiologic classification of human papillomavirus types associated with cervical cancer

Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study

Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease.

Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study

Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination

Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.

Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study.

Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008.

P304

605-615

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0009922817691826

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28503996

http://www.w3.org/2001/XMLSchema#string

P921

immunization